BioSante Pharma (BPAX) Tops Q3 EPS by 2c; Bio-T-Gel Gets New PDUFA Date
Tweet
Share
E-mailGet Alerts BPAX Hot Sheet
Price: $1.09 --0%
Financial Fact:
Research and development: 1.04M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Research and development: 1.04M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) reported Q3 EPS of ($0.12), $0.02 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $182,780 versus the consensus estimate of $30,000.
Announced its Bio-T-Gel was assigned a new PDUFA date of Feb. 14th, 2012.
Announced its Bio-T-Gel was assigned a new PDUFA date of Feb. 14th, 2012.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
- SuperCom (SPCB) Tops Q3 EPS by 43c
- McGraw Hill (MH) Tops Q2 EPS by 11c, Beats on Revenue; Offers FY26 Guidance
Create E-mail Alert Related Categories
Earnings, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
